A male patient in first remission of acute myeloid leukemia was offered a hemopoietic cell transplant from an unrelated female donor. He received reduced-intensity conditioning (RIC) with Fludarabine 30 mg/m2 iv × 5 day, Busulphan 3.2 mg/kg iv × 2 days, and Alemtuzumab 20 mg/day iv × 5 days, followed by donor blood stem cell infusion. The cell dose was 3.7 × 106 CD34+ cells per kilogram recipient weight. Cyclosporine A was administered from day +1.
Acute Myeloid Leukemia Autoimmune Hemolytic Anemia Donor Type Recipient Weight Recipient Type
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687–94.PubMedCrossRefGoogle Scholar
Mijovic A, Abdallah A, Pearce L, et al. Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimes. Br J Haematol. 2008;142:444–52.PubMedCrossRefGoogle Scholar